Targeting Glutamine Metabolism in Prostate Cancer

Targeting Glutamine Metabolism in Prostate Cancer

Glutamine is a conditionally essential amino acid important for cancer cell proliferation through intermediary metabolism leading to de novo synthesis of purine and pyrimidine nucleotides, hexosamine biosytnehsis, fatty acid synthesis through reductive carboxylation, maintenance of redox homeostasis...

Full description

Bibliographic Details
Main Authors:	Neil Bhowmick, Edwin Posadas, Leigh Ellis, Stephen J Freedland, Dolores Di Vizio, Michael R Freeman, Dan Theodorescu, Robert Figlin, Jun Gong
Format:	Article
Language:	English
Published:	IMR Press 2023-01-01
Series:	Frontiers in Bioscience-Elite
Subjects:	glutamine prostate cancer glutaminase myc androgen receptor mtor castrate-resistance pten
Online Access:	https://www.imrpress.com/journal/FBE/15/1/10.31083/j.fbe1501002

Similar Items

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
by: Jamie A. Kmak, et al.
Published: (2020-04-01)

Targeting Glutamine Addiction in Gliomas
by: Marta Obara-Michlewska, et al.
Published: (2020-01-01)

The role of glutamine metabolism in castration-resistant prostate cancer
by: Bing Zhao, et al.
Published: (2023-01-01)

Research Progress in Improving Efficacy of Radiotherapy by Targeting Glutamine Metabolism
by: QIAO Wanjia, et al.
Published: (2023-03-01)

Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of <i>Pten</i>-Deficient Prostate Cancer
by: Marco A. De Velasco, et al.
Published: (2021-08-01)

Metformin modifies glutamine metabolism in an in vitro and in vivo model of hepatic encephalopathy
by: Antonio Gil-Gómez, et al.

Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer
by: Manish Thiruvalluvan, et al.
Published: (2022-05-01)

Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability
by: Martina Chiu, et al.
Published: (2020-11-01)

The Pleiotropic Effects of Glutamine Metabolism in Cancer
by: Alex J. Bott, et al.
Published: (2019-06-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

MYC Rules: Leading Glutamine Metabolism toward a Distinct Cancer Cell Phenotype
by: Vincent Tambay, et al.
Published: (2021-09-01)

Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer
by: AD Zarrabi, et al.
Published: (2011-06-01)

Targeting Glutaminase by Natural Compounds: Structure-Based Virtual Screening and Molecular Dynamics Simulation Approach to Suppress Cancer Progression
by: Shams Tabrez, et al.
Published: (2022-08-01)

α-Ketoglutaramate—A key metabolite contributing to glutamine addiction in cancer cells
by: Arthur J. L. Cooper, et al.
Published: (2022-11-01)

Glutamine Produces Ammonium to Tune Lysosomal pH and Regulate Lysosomal Function
by: Jian Xiong, et al.
Published: (2022-12-01)

Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster?
by: Jie Jiang, et al.
Published: (2019-06-01)

Clinical relevance of androgen receptor alterations in prostate cancer
by: Emma Jernberg, et al.
Published: (2017-10-01)

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
by: Anis Gasmi, et al.
Published: (2021-12-01)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
by: Jian Pan, et al.
Published: (2022-12-01)

Glutamine Deficiency Promotes Immune and Endothelial Cell Dysfunction in COVID-19
by: William Durante
Published: (2023-04-01)

Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants
by: Demitria M. Vasilatis, et al.
Published: (2023-04-01)

Disruption of prostate epithelial differentiation pathways and prostate cancer development
by: Sander B Frank, et al.
Published: (2013-10-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

SIRT5 Activation and Inorganic Phosphate Binding Reduce Cancer Cell Vitality by Modulating Autophagy/Mitophagy and ROS
by: Federica Barreca, et al.
Published: (2023-08-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

Expression and ERG regulation of PIM kinases in prostate cancer
by: Sini K. Eerola, et al.
Published: (2021-05-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Glutamine addiction: an Achilles heel in esophageal cancers with dysregulation of CDK4/6
by: Shuo Qie, et al.
Published: (2019-07-01)

AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
by: Elisabetta Tortorella, et al.
Published: (2023-01-01)

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
by: Chi-Shin Tseng, et al.
Published: (2023-06-01)

Androgen-Driven Fusion Genes and Chimeric Transcripts in Prostate Cancer
by: Mauro Scaravilli, et al.
Published: (2021-02-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Metabolic Signaling Cascades Prompted by Glutaminolysis in Cancer
by: Raj Shah, et al.
Published: (2020-09-01)

Brain glutaminases
by: Márquez Javier, et al.
Published: (2010-05-01)

Economical impact of orchiectomy for advanced prostate cancer
by: Paula Adriano A. P. de, et al.
Published: (2003-01-01)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01)

Hormone-Glutamine Metabolism: A Critical Regulatory Axis in Endocrine-Related Cancers
by: Fengyuan Xu, et al.
Published: (2022-09-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Evaluation of Glutaminase Expression in Prostate Adenocarcinoma and Correlation with Clinicopathologic Parameters
by: Zin W. Myint, et al.
Published: (2021-04-01)